Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
We agree with the comments1 on Boag and Kelly's
editorial2 about the recommendations made by the chief
medical officer's expert advisory group on Chlamydia
trachomatis. We wish to raise another issue.
The laboratories associated with the genitourinary medicine
clinics in the two pilot projects evaluating the proposed screening will use molecular procedures (ligase chain reaction or polymerase chain reaction) and not the less sensitive tests (enzyme immunoassays) used by most laboratories testing for C trachomatis in
England and Wales. Support exists for this proposal.3
However, the use of the most sensitive tests should extend beyond this.
About 30% of women, symptomatic or asymptomatic, with C
trachomatis infection attending genitourinary clinics have
small numbers of organisms in cervical specimens.4 As most
clinics rely on enzyme immunassays the infection will not be diagnosed
in most of these women. We calculate, on the basis of about 500 000
women attending genitourinary
Read all Rapid Responses